Where Will TJX Companies Stock Be in 10 Years?
Off-price retail is as popular as ever thanks to social…
Sell
23
CRBU Quote, Financials, Valuation and Earnings
Last price:
$1.53
Seasonality move
:
-30.52%
Day range:
$1.52 - $1.58
52-week range:
$1.50 - $8.33
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.96x
P/B ratio:
0.49x
Volume:
1M
Avg. volume:
1.5M
1-year change:
-70.58%
Market cap:
$138.5M
Revenue:
$34.5M
EPS (TTM):
-$1.66
Analysts' Opinion
-
Consensus RatingCaribou Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.25, Caribou Biosciences has an estimated upside of 766.01% from its current price of $1.53.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $1.53.
Fair Value
-
According to the consensus of 7 analysts, Caribou Biosciences has 766.01% upside to fair value with a price target of $13.25 per share.
CRBU vs. S&P 500
-
Over the past 5 trading days, Caribou Biosciences has underperformed the S&P 500 by -9.35% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Caribou Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Caribou Biosciences revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Caribou Biosciences reported revenues of $2M.
Earnings Growth
-
Caribou Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Caribou Biosciences reported earnings per share of -$0.38.
Enterprise value:
-89.6M
EV / Invested capital:
--
Price / LTM sales:
11.96x
EV / EBIT:
--
EV / Revenue:
-7.81x
PEG ratio (5yr expected):
-0.09x
EV / Free cash flow:
0.68x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-36.78%
Net Income Margin (TTM):
-1290.81%
Return On Equity:
-43.52%
Return On Invested Capital:
-43.52%
Operating Margin:
-1889.23%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $12.7M | $34.6M | $11.5M | $23.7M | $2M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$96.2M | -$109.2M | -$165.2M | -$14.6M | -$38.2M | |
| EBITDA | -$94.8M | -$105.9M | -$161.7M | -$13.1M | -$37.1M | |
| Diluted EPS | -$1.51 | -$1.50 | -$1.66 | -$0.12 | -$0.38 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $449M | $306.9M | $350.7M | $237.4M | |
| Total Assets | -- | $462M | $398.8M | $457.5M | $344.3M | |
| Current Liabilities | -- | $26.2M | $28.8M | $24.6M | $32.2M | |
| Total Liabilities | -- | $57.6M | $74.7M | $59.3M | $63.1M | |
| Total Equity | -- | $404.4M | $324.1M | $398.3M | $281.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$87.3M | -$97M | -$124.1M | -$28.8M | -$32.7M | |
| Cash From Investing | -$268.4M | -$35.5M | $39.2M | -$68.5M | $26.5M | |
| Cash From Financing | $2.5M | $154.5M | $12.8M | $135.1M | $244K | |
| Free Cash Flow | -$93M | -$108.3M | -$132.4M | -$33.5M | -$33.3M | |
CRBU
Sector
Market Cap
$138.5M
$44.9M
Price % of 52-Week High
18.37%
46.55%
Dividend Yield
0%
0%
Shareholder Yield
-6.83%
-0.75%
1-Year Price Total Return
-70.58%
-33.54%
Beta (5-Year)
--
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.62
200-day SMA
Sell
Level
$2.35
Bollinger Bands (100)
Sell
Level
1.72 - 2.22
Chaikin Money Flow
Sell
Level
-69.6M
20-day SMA
Sell
Level
$1.69
Relative Strength Index (RSI14)
Sell
Level
35.29
ADX Line
Sell
Level
10.59
Williams %R
Buy
Level
-94.4444
50-day SMA
Sell
Level
$1.98
MACD (12, 26)
Sell
Level
-0.11
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
32.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.8521)
Buy
CA Score
(Annual)
Level (-0.2137)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.2761)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Stock Forecast FAQ
In the current month, CRBU has received 5 Buy ratings 2 Hold ratings, and 0 Sell ratings. The CRBU average analyst price target in the past 3 months is $13.25.
-
Where Will Caribou Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Caribou Biosciences share price will rise to $13.25 per share over the next 12 months.
-
What Do Analysts Say About Caribou Biosciences?
Analysts are divided on their view about Caribou Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Caribou Biosciences is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Caribou Biosciences's Price Target?
The price target for Caribou Biosciences over the next 1-year time period is forecast to be $13.25 according to 7 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is CRBU A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Caribou Biosciences is a Buy. 5 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CRBU?
You can purchase shares of Caribou Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Caribou Biosciences shares.
-
What Is The Caribou Biosciences Share Price Today?
Caribou Biosciences was last trading at $1.53 per share. This represents the most recent stock quote for Caribou Biosciences. Yesterday, Caribou Biosciences closed at $1.53 per share.
-
How To Buy Caribou Biosciences Stock Online?
In order to purchase Caribou Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will CVS Health Stock Recover?
It’s been a treacherous journey for CVS Health Corporation (NYSE:CVS)…
Why Is AT&T Stock Dropping?
The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
QMCO alert for Jan 16
Quantum [QMCO] is down 0% over the past day.
Buy
51
QRVO alert for Jan 16
Qorvo [QRVO] is down 0% over the past day.
Sell
31
ATEX alert for Jan 16
Anterix [ATEX] is down 0% over the past day.
